New Phesi global analysis sees breast cancer retain position as most studied disease area in 2022
The analysis of 80,917 trial records reveals that breast cancer retained its position as the most-studied disease area, followed by COVID-19. Three of the top five most-studied disease areas fell within oncology, with prostate cancer the third most-studied disease, solid tumours fourth, and stroke fifth. Both prostate cancer and stroke enter the top five in 2022, replacing non-small cell lung cancer and multiple myeloma in 2021.
Number of collagen clinical trials more than doubled since 2010, Phesi analysis shows
Phesi, a global provider of patient-centric data analytics, has today published a new analysis of 2,358 clinical trials involving collagen to highlight the growing investment being placed into the protein. The analysis shows a steady, linear increase in new collagen clinical trials over the previous decade (Fig. 1). In the first 10 months of 2022, there were more than 225 new trials into collagen, compared with 125 in 2012.
Phesi launches AI-driven Trial Accelerator™ to enable simulated trials and deliver comprehensive view of the patient throughout clinical development and commercialization
Phesi, a global provider of patient-centric data analytics, has today launched its AI-driven Trial Accelerator™ platform to facilitate real-time scenario modelling across patient, endpoint, country, and investigator site allocation. Underpinned by the world’s largest, most dynamic clinical trial database, the SaaS platform enables clinical development personnel to simulate trial outcomes and reduce unnecessary protocol amendments. Industry data show that the average phase III protocol experiences 3.3 substantial amendments. With cost estimated at $500k per amendment and adding 5.2 months of implementation time, Phesi’s Trial Accelerator™ platform can save sponsors up to $1,500,000 and 15 months per trial.
Almost half of Ukraine’s clinical trials to find new therapies are still recruiting patients despite ongoing conflict, Phesi analysis shows
Phesi has today published its latest update on the significant impact of the war in Ukraine on clinical development in the region. Phesi’s analysis of recruiting investigator sites (those actively enrolling patients) finds that since the beginning of 2022 to the 1st Oct 2022, the number of recruiting sites has fallen from 1,814 to 940 (48%) in Ukraine, yet the other half are continuing to recruit. In Russia, recruiting sites have fallen from 3,412 to 1,638 (52%) and in Belarus from 84 to 33 (55%).